Author: admin

DelveInsight’s “Hypophosphatasia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hypophosphatasia, historical and forecasted epidemiology as well as the Hypophosphatasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Hypophosphatasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypophosphatasia Market Forecast

Some of the key facts of the Hypophosphatasia Market Report:

• The Hypophosphatasia market size was valued at ~USD 880 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• The pipeline for Hypophosphatasia is not very robust, consisting of REC-01, ALXN1850, and others which are expected to launch during the forecast period [2022-2032]

• According to DelveInsight’s analysis, the diagnosed prevalent cases of Hypophosphatasia in the 7MM were estimated to be around 6,500 in 2023. This number is expected to rise by 2034 due to increased disease awareness among healthcare professionals and the general public worldwide.

• In 2023, the US reported the highest diagnosed prevalence of hypophosphatasia among the 7MM, with approximately 6,000 cases. These numbers are expected to grow from 2024 to 2034, largely due to advancements in genetic testing that have enabled expanded newborn screening programs across the country.

• Among the EU4 countries and the UK, Germany reported the highest number of diagnosed hypophosphatasia cases, with about 84 cases, followed by France with 69 cases, and the UK with 68 cases. These numbers are expected to increase by 2034, driven by a heightened focus on research and clinical trials for the disease.

• In the UK, mild hypophosphatasia cases accounted for nearly 82%, moderate cases for 16%, and severe cases for 2% in 2023. The number of cases for each severity level is expected to rise by 2034.

• Key Hypophosphatasia Companies: PuREC, AstraZeneca, Ultragenyx Pharmaceutical Inc., Alexion, and others

• Key Hypophosphatasia Therapies: REC-01, ALXN1850, BPS804, asfotase alfa, and others

• The Hypophosphatasia epidemiology based on severity-specific cases analyzed that mild Hypophosphatasia was most prevalent in the US, followed by moderate and severe Hypophosphatasia

• The Hypophosphatasia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypophosphatasia pipeline products will significantly revolutionize the Hypophosphatasia market dynamics.

Hypophosphatasia Overview

Hypophosphatasia is a rare, inherited metabolic disorder caused by mutations in the ALPL gene, which affects the production of alkaline phosphatase (ALP) enzyme. This enzyme is essential for the proper mineralization of bones and teeth. In HPP, reduced ALP activity leads to defective bone development, resulting in conditions like rickets in children or osteomalacia in adults. Symptoms vary widely, ranging from severe skeletal abnormalities in infancy to milder issues in adulthood. The condition can also cause dental problems, muscle weakness, and respiratory complications. Hypophosphatasia is managed through supportive care and, in some cases, enzyme replacement therapy.

Get a Free sample for the Hypophosphatasia Market Report

https://www.delveinsight.com/sample-request/hypophosphatasia-market

Hypophosphatasia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hypophosphatasia Epidemiology Segmentation:

The Hypophosphatasia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Hypophosphatasia

• Prevalent Cases of Hypophosphatasia by severity

• Gender-specific Prevalence of Hypophosphatasia

• Diagnosed Cases of Episodic and Chronic Hypophosphatasia

Download the report to understand which factors are driving Hypophosphatasia epidemiology trends @ Hypophosphatasia Epidemiology Forecast

Hypophosphatasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypophosphatasia market or expected to get launched during the study period. The analysis covers Hypophosphatasia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hypophosphatasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hypophosphatasia Therapies and Key Companies

• REC-01: PuREC

• ALXN1850: AstraZeneca

• BPS804: Ultragenyx Pharmaceutical Inc

Discover more about therapies set to grab major Hypophosphatasia market share @ Hypophosphatasia Treatment Market

Hypophosphatasia Market Strengths

• Advancements in understanding the pathophysiology and genetics of Hypophosphatasia, thereby elucidating new targets for treatment

• The approval of ERT by various regulatory authorities is a game changer, improving clinical manifestations, survival, and QoL

Hypophosphatasia Market Barriers

• Developing specific biochemical biomarker-based assays with an increased understanding of differential diagnosis among physicians will lead to improvements in diagnosis, thus opening the windows of opportunity for new treatment options

• There is a need for pharmacotherapeutic interventions for milder adult-onset of disease, which has little mortality and a high disease burden

Scope of the Hypophosphatasia Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Hypophosphatasia Companies: PuREC, AstraZeneca, Ultragenyx Pharmaceutical Inc., Alexion, and others

• Key Hypophosphatasia Therapies: REC-01, ALXN1850, BPS804, asfotase alfa, and others

• Hypophosphatasia Therapeutic Assessment: Hypophosphatasia current marketed and Hypophosphatasia emerging therapies

• Hypophosphatasia Market Dynamics: Hypophosphatasia market drivers and Hypophosphatasia market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Hypophosphatasia Unmet Needs, KOL’s views, Analyst’s views, Hypophosphatasia Market Access and Reimbursement

To know more about Hypophosphatasia companies working in the treatment market, visit @ Hypophosphatasia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Hypophosphatasia Market Report Introduction

2. Executive Summary for Hypophosphatasia

3. SWOT analysis of Hypophosphatasia

4. Hypophosphatasia Patient Share (%) Overview at a Glance

5. Hypophosphatasia Market Overview at a Glance

6. Hypophosphatasia Disease Background and Overview

7. Hypophosphatasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Hypophosphatasia

9. Hypophosphatasia Current Treatment and Medical Practices

10. Hypophosphatasia Unmet Needs

11. Hypophosphatasia Emerging Therapies

12. Hypophosphatasia Market Outlook

13. Country-Wise Hypophosphatasia Market Analysis (2020–2034)

14. Hypophosphatasia Market Access and Reimbursement of Therapies

15. Hypophosphatasia Market Drivers

16. Hypophosphatasia Market Barriers

17. Hypophosphatasia Appendix

18. Hypophosphatasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hypophosphatasia Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | PuREC, AstraZeneca, Ultragenyx Pharma, Alexion

“Mydriasis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mydriasis Market.

The Mydriasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Mydriasis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Mydriasis treatment therapies with a considerable amount of success over the years.

• Mydriasis companies working in the treatment market are Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd, and others, are developing therapies for the Mydriasis treatment

• Emerging Mydriasis therapies in the different phases of clinical trials are- RYZUMVI (Phentolamine Ophthalmic Solution 0.75%), MYDCOMBI, OMIDRIA, MydCombi, CTO0303-A, and others are expected to have a significant impact on the Mydriasis market in the coming years.

• In September 2024, Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for retinal and refractive eye disorders, announced the publication of full results from two pivotal Phase 3 trials (MIRA-2 and MIRA-3) in the peer-reviewed journal Ophthalmology. The trials evaluated the safety and efficacy of RYZUMVI™ (Phentolamine Ophthalmic Solution 0.75%) for treating pharmacologically-induced mydriasis. The results showed that Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, effectively reversed pupil dilation with a favorable safety profile.

Mydriasis Overview

Mydriasis is the medical term for the dilation of the pupils, often beyond their normal size, which can occur due to various factors. It can result from physiological responses to low light, emotional arousal, or the use of certain medications like anticholinergics and sympathomimetics. Mydriasis can also indicate underlying medical conditions such as brain injury, drug intoxication, or neurological disorders. Unlike normal pupil dilation, mydriasis is not always responsive to light changes, making it a clinical sign that may require further evaluation.

Get a Free Sample PDF Report to know more about Mydriasis Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/mydriasis-pipeline-insight

Emerging Mydriasis Drugs Under Different Phases of Clinical Development Include:

• RYZUMVI (Phentolamine Ophthalmic Solution 0.75%): Viatris/Ocuphire Pharma

• MYDCOMBI: Eyenovia

• OMIDRIA: Rayner Surgical/Omeros

• MydCombi: Eyenovia Inc.

• CTO0303-A: Taejoon Pharmaceutical Co., Ltd.

Mydriasis Route of Administration

Mydriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Mydriasis Molecule Type

Mydriasis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Mydriasis Pipeline Therapeutics Assessment

• Mydriasis Assessment by Product Type

• Mydriasis By Stage and Product Type

• Mydriasis Assessment by Route of Administration

• Mydriasis By Stage and Route of Administration

• Mydriasis Assessment by Molecule Type

• Mydriasis by Stage and Molecule Type

DelveInsight’s Mydriasis Report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Mydriasis product details are provided in the report. Download the Mydriasis pipeline report to learn more about the emerging Mydriasis therapies

Some of the key companies in the Mydriasis Therapeutics Market include:

Key companies developing therapies for Mydriasis are – Ocuphire Pharma, Théa Laboratories, Omeros Corporation, and others.

Mydriasis Pipeline Analysis:

The Mydriasis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Mydriasis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mydriasis Treatment.

• Mydriasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Mydriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mydriasis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Mydriasis drugs and therapies

Mydriasis Pipeline Market Drivers

• Increasing Prevalence of Eye Conditions, Technological Advancements, Aging Population, Increased Awareness of Eye Health, Surge in Ophthalmic Surgeries, are some of the important factors that are fueling the Mydriasis Market.

Mydriasis Pipeline Market Barriers

• However, High Cost of Treatment, Side Effects of Mydriatic Agents, Limited Availability in Low-Resource Settings, Competition from Alternative Therapies, Stringent Regulatory Approval, and other factors are creating obstacles in the Mydriasis Market growth.

Scope of Mydriasis Pipeline Drug Insight

• Coverage: Global

• Key Mydriasis Companies: Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd, and others

• Key Mydriasis Therapies: RYZUMVI (Phentolamine Ophthalmic Solution 0.75%), MYDCOMBI, OMIDRIA, MydCombi, CTO0303-A, and others

• Mydriasis Therapeutic Assessment: Mydriasis current marketed and Mydriasis emerging therapies

• Mydriasis Market Dynamics: Mydriasis market drivers and Mydriasis market barriers

Request for Sample PDF Report for Mydriasis Pipeline Assessment and clinical trials

Table of Contents

1. Mydriasis Report Introduction

2. Mydriasis Executive Summary

3. Mydriasis Overview

4. Mydriasis- Analytical Perspective In-depth Commercial Assessment

5. Mydriasis Pipeline Therapeutics

6. Mydriasis Late Stage Products (Phase II/III)

7. Mydriasis Mid Stage Products (Phase II)

8. Mydriasis Early Stage Products (Phase I)

9. Mydriasis Preclinical Stage Products

10. Mydriasis Therapeutics Assessment

11. Mydriasis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Mydriasis Key Companies

14. Mydriasis Key Products

15. Mydriasis Unmet Needs

16 . Mydriasis Market Drivers and Barriers

17. Mydriasis Future Perspectives and Conclusion

18. Mydriasis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc

“Ulcerative Colitis Drugs Market”

(Albany, USA) DelveInsight’s Ulcerative Colitis Market report offers a detailed comprehension of the Ulcerative Colitis market size by treatment, epidemiology, and emerging therapies. The report also provides an understanding of Ulcerative Colitis market share of the individual therapies, current and forecasted Ulcerative Colitis market size from 2020 to 2034 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

To know more in detail about Ulcerative Colitis Market report offerings, click here @ Ulcerative Colitis Market Forecast

Key highlights from the Ulcerative Colitis Market Insight report

• According to DelveInsight, the Ulcerative Colitis market size is expected to grow at a decent CAGR by 2034.

• The total Ulcerative Colitis Market Size in the 7MM was approximately USD 8090 million in 2022 and is projected to increase during the forecast period (2023–2034).
• In the United States, the total number of diagnosed prevalent cases of ulcerative colitis was 1,437,600 in 2022.

• Leading Ulcerative Colitis companies working proactively in the therapeutic market are Janssen Pharmaceuticals, Takeda Pharmaceuticals, Pfizer, EA Pharma, Kissei Pharma, Gilead Sciences, Galapagos NV, Celgene (Bristol-Myers Squibb), AbbVie, Arena Pharmaceuticals, Reistone Biopharma, Landos Biopharma, Bridge Biotherapeutics, Applied Molecular Transport, AbGenomics (AltruBio), Abivax, Connect Biopharma, Boehringer Ingelheim, Eli Lilly and Company, InDex Pharmaceuticals, Bristol-Myers Squibb, Protagonist Therapeutics, Mesoblast Ltd, and several others in the clinical development stage for Ulcerative Colitis will lead to a significant increase in the market size during the forecast period.
• The key Ulcerative Colitis therapies expected to launch in the market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), Skyrizi (Risankizumab), Mirikizumab (LY-3074828), Etrasimod, Tremfya (Guselkumab), Izencitinib (TD-1473/ JNJ 8398), BT-11, and others.

• According to DelveInsight analysis, the Ulcerative Colitis market is expected to rise in the coming years due to the entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, increasing prevalence of Ulcerative Colitis, and new biomarkers for diagnosis of Ulcerative Colitis.
• On January 2024, Palatin Technologies announced results of a Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, PK and Biomarkers with Oral Colon Delivery PL8177 in Adult Subjects with Active Ulcerative Colitis.
• On April 2024, Vedanta Biosciences announced results of A Phase 2 double-blind, placebo-controlled, randomized study to evaluate the safety, efficacy, and microbiota changes of VE202 in biologic-naïve patients with mild to moderate Ulcerative Colitis. In Parts 1 and 2 of the study, patients will receive VE202 or placebo for 8 weeks or 2 weeks. In Part 3, patients will be followed for safety for 1 year from the start of treatment.
• On March 2024, Eli Lilly announced results of a Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship with Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab.
• On February 2024, AbbVie announced results of a study about early therapeutic response and predictivity of long-term effectiveness of upadacitinib in ulcerative colitis (Europe).

For further information on Market Impact by Therapies, Download Ulcerative Colitis Market sample @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market

Ulcerative Colitis Overview

Two major types of Inflammatory Bowel Disease (IBD) are Ulcerative Colitis (UC) and Crohn’s Disease (CD). Ulcerative Colitis is limited to the colon or large intestine. Approximately 10% of cases of IBD exhibit the features of both Ulcerative Colitis and Crohn’s Disease. These are typically known as Indeterminate Colitis (IC).

There are different types of Ulcerative Colitis, categorized by the cause of the disease: Ulcerative proctitis, Proctosigmoiditis, Left-sided colitis (also limited or distal colitis), Pancolitis, and Extensive Colitis. There is no single test to diagnose Ulcerative Colitis, instead, the IBD team takes into consideration the symptoms together with the results of Endoscopies, Biopsies, Blood and Stool tests, X-rays, and Imaging Procedures.

Ulcerative Colitis Epidemiology Segmentation

DelveInsight’s analysts indicate that the total diagnosed cases of Ulcerative Colitis in the 7MM were 1,577,979 in 2020. These cases are expected to rise by 2034, during the forecast period.

The Ulcerative Colitis market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

• Total Prevalent Ulcerative Colitis Cases
• Total Diagnosed Prevalent Ulcerative Colitis Cases
• Age-Specific Diagnosed Prevalent Cases of Ulcerative Colitis
• Severity-Specific Diagnosed Prevalent Cases of Ulcerative Colitis
• Total Treated Ulcerative Colitis Cases

Download Ulcerative Colitis Market sample to know more about the epidemiology and market trends @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market

Ulcerative Colitis Pipeline Therapies and Key Companies

• Jyseleca (filgotinib): Gilead Sciences/Galapagos NV
• Rinvoq (Upadacitinib) & Skyrizi(Risankizumab): AbbVie
• Risankizumab (ABBV-066): AbbVie and Boehringer Ingelheim
• Mirikizumab (LY-3074828): Eli Lilly and Company
• Etrasimod: Arena Pharmaceuticals
• Tremfya (Guselkumab): Janssen (Johnson & Johnson)
• Izencitinib (TD-1473/ JNJ 8398): Theravance Biopharma/Johnson & Johnson
• BT-11: Landos Biopharma

Ulcerative Colitis Market Dynamics

The current therapeutic landscape of Ulcerative Colitis in the 7MM is driven by several approved therapies. Also, the Ulcerative Colitis market is expected to surge due to factors such as the increasing prevalence of Ulcerative Colitis, entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, new biomarkers for diagnosis of Ulcerative Colitis and also the involvement of digital technology for diagnosis and treatment.

A high number of undiagnosed and unreported cases contribute to the lack of awareness of Ulcerative Colitis. The entry of biosimilars in the Ulcerative Colitis Market, insufficient knowledge of the disease, and significant drawbacks of existing therapeutic options may act as certain obstructions in the Ulcerative Colitis market.

For further information on Market Impact by Therapies, Download Ulcerative Colitis Market sample @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market

Scope of the Ulcerative Colitis Market Report

• Study Period: 2020-34
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ulcerative Colitis Companies: Takeda Pharmaceutical, Pfizer, Celgene (Bristol-Myers Squibb), Gilead Sciences, Galapagos NV, AbbVie, Eli Lilly and Company, Arena Pharmaceuticals, Janssen (Johnson & Johnson), Theravance Biopharma, Landos Biopharma
• Key Ulcerative Colitis Drugs: Jyseleca (filgotinib), Rinvoq (Upadacitinib), Skyrizi(Risankizumab), Mirikizumab (LY-3074828), Etrasimod, Tremfya (Guselkumab), Izencitinib (TD-1473/ JNJ 8398), BT-11
• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and emerging therapies
• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and barriers
• Competitive Intelligence Analysis: Porter’s five forces, SWOT analysis, PESTLE analysis, Market entry strategies, BCG Matrix, Unmet Needs
• KOL views
• Reimbursement Scenario

Download Market sample to know more about the recent happenings in the Ulcerative colitis therapeutic landscape @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market

Table of Contents

1. Key Insights

2. Report Introduction of Ulcerative Colitis

3. Ulcerative Colitis Market Overview at a Glance

4. Executive Summary of Ulcerative Colitis

5. Ulcerative Colitis Epidemiology and Market Forecast Flow

6. Ulcerative Colitis: Disease Background and Overview

7. Ulcerative Colitis Diagnosis

8. Ulcerative Colitis Current Treatment

9. Ulcerative Colitis Epidemiology and Patient Population

10. Ulcerative Colitis Patient Journey

11. Key Endpoints in Ulcerative Colitis Clinical Trials

12. Ulcerative Colitis Marketed Therapies of Ulcerative Colitis

13. Ulcerative Colitis Emerging Therapies

14. Conjoint Analysis of Ulcerative Colitis

15. Ulcerative Colitis: Seven Major Market Analysis

16. The United States Market Size

17. Ulcerative Colitis Market Access and Reimbursement

18. Ulcerative Colitis Market Drivers

19. Ulcerative Colitis Market Barriers

20. Ulcerative Colitis SWOT Analysis

21. Ulcerative Colitis Unmet Needs

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

About DelveInsight

DelveInsight is a pioneer in stipulating state-of-the-art services to the clients, also serving as a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ulcerative Colitis Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical trials, Medication, Therapies, Prevalence and Companies by DelveInsight

“Traumatic Brain Injury Treatment Market”

DelveInsight’s “Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Traumatic Brain Injury, historical and forecasted epidemiology as well as the Traumatic Brain Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Traumatic Brain Injury, offering comprehensive insights into the Traumatic Brain Injury revenue trends, prevalence, and treatment landscape. The report delves into key Traumatic Brain Injury statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Traumatic Brain Injury therapies. Additionally, we cover the landscape of Traumatic Brain Injury clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Traumatic Brain Injury treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Traumatic Brain Injury space.

To Know in detail about the Traumatic Brain Injury market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Traumatic Brain Injury Market Forecast

Some of the key facts of the Traumatic Brain Injury Market Report:

• The Traumatic Brain Injury market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• The total market size for TBI in the US was approximately USD 5 billion in 2023. DelveInsight’s analysis forecasts market growth driven by the introduction of new therapies. As a result, the market size is expected to expand during the study period from 2020 to 2034.
• DelveInsight’s analysts estimate that the total market size for TBI in the EU4 and the UK was approximately USD 900 million in 2023, with expectations for further growth during the forecast period from 2024 to 2034.
• The market size for TBI in Japan was around USD 380 million in 2023, representing 6% of the total market across the 7MM, and is projected to increase by 2034.
• Key Traumatic Brain Injury Companies: VeriNOS Pharmaceuticals GmbH, Cellvation, Inc., Abalonex, LLC, The SanBio Group, Hope Biosciences, CereMark Pharma, LLC, Hamad Medical Corporation, Supernus Pharmaceuticals, Inc., Merz Pharmaceuticals GmbH, and others
• Key Traumatic Brain Injury Therapies: Ronopterin (VAS203), CEVA101, ABX-101, SB623 (vandefitemcel), Autologous HB-adMSCs, [F-18]Flornaptitril, ABX-101, Propranolol, MYOBLOC, NT 201, and others
• The Traumatic Brain Injury market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Traumatic Brain Injury pipeline products will significantly revolutionize the Traumatic Brain Injury market dynamics.
• According to DelveInsight’s analysis, the total number of incident cases of Traumatic Brain Injury (TBI) in the 7MM was approximately 4,254 thousand in 2023 and is expected to increase at a significant compound annual growth rate (CAGR) throughout the forecast period from 2024 to 2034.
• Among the EU4 and UK countries, Germany reported the highest number of incident cases of Traumatic Brain Injury (TBI) in 2023, with 238 thousand cases, while Spain had the lowest at 134 thousand cases. The number of cases is anticipated to increase in the EU4 and the UK.
• The estimates indicate that the incident population of Traumatic Brain Injury (TBI) in Japan is projected to be 325 thousand cases in 2023, but this number is expected to decline by 2034.
• In 2023, 66% of males and 34% of females in the 7MM experienced Traumatic Brain Injury (TBI). These cases are expected to increase during the forecast period from 2024 to 2034.

Traumatic Brain Injury Overview

Traumatic Brain Injury (TBI) is a serious injury to the brain caused by an external force, such as a blow or jolt to the head, a fall, or an accident. TBIs can range from mild concussions to severe brain damage, leading to various physical, cognitive, and emotional symptoms. Common symptoms include headaches, confusion, dizziness, memory problems, and difficulty concentrating. Treatment may involve medication, rehabilitation, and supportive care, depending on the severity of the injury. Early diagnosis and intervention are crucial for improving outcomes and minimizing long-term effects.

Get a Free sample for the Traumatic Brain Injury Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/traumatic-brain-injury-market

Traumatic Brain Injury Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Traumatic Brain Injury Epidemiology Segmentation:

The Traumatic Brain Injury market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Traumatic Brain Injury
• Prevalent Cases of Traumatic Brain Injury by severity
• Gender-specific Prevalence of Traumatic Brain Injury
• Diagnosed Cases of Episodic and Chronic Traumatic Brain Injury

Download the report to understand which factors are driving Traumatic Brain Injury epidemiology trends @ Traumatic Brain Injury Epidemiology Forecast

Traumatic Brain Injury Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Traumatic Brain Injury market or expected to get launched during the study period. The analysis covers Traumatic Brain Injury market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Traumatic Brain Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Traumatic Brain Injury Therapies and Key Companies

• Ronopterin (VAS203): VeriNOS Pharmaceuticals GmbH
• CEVA101: Cellvation, Inc.
• ABX-101: Abalonex, LLC
• SB623 (vandefitemcel): The SanBio Group
• Autologous HB-adMSCs: Hope Biosciences
• [F-18]Flornaptitril: CereMark Pharma, LLC
• ABX-101: Abalonex, LLC
• Propranolol: Hamad Medical Corporation
• MYOBLOC: Supernus Pharmaceuticals, Inc.
• NT 201: Merz Pharmaceuticals GmbH

Discover more about therapies set to grab major Traumatic Brain Injury market share @ Traumatic Brain Injury Treatment Landscape

Traumatic Brain Injury Market Strengths

• Traumatic Brain Injury is a significant global health issue, with a growing number of cases due to a rising number of head injuries and increasing awareness.
• Advances in medical technology have led to better diagnosis, treatment, and management options for Traumatic Brain Injury, including neuroimaging techniques and neuroprotective drugs.

Traumatic Brain Injury Market Opportunities

• The therapeutic market of Traumatic Brain Injury is very scarce, creating an opportunity for key market players to enter the Traumatic Brain Injury market.
• The trend toward precision medicine opens avenues for developing targeted treatments, allowing for more effective and personalized interventions in Traumatic Brain Injury management.

Scope of the Traumatic Brain Injury Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Traumatic Brain Injury Companies: VeriNOS Pharmaceuticals GmbH, Cellvation, Inc., Abalonex, LLC, The SanBio Group, Hope Biosciences, CereMark Pharma, LLC, Hamad Medical Corporation, Supernus Pharmaceuticals, Inc., Merz Pharmaceuticals GmbH, and others
• Key Traumatic Brain Injury Therapies: Ronopterin (VAS203), CEVA101, ABX-101, SB623 (vandefitemcel), Autologous HB-adMSCs, [F-18]Flornaptitril, ABX-101, Propranolol, MYOBLOC, NT 201, and others
• Traumatic Brain Injury Therapeutic Assessment: Traumatic Brain Injury current marketed and Traumatic Brain Injury emerging therapies
• Traumatic Brain Injury Market Dynamics: Traumatic Brain Injury market drivers and Traumatic Brain Injury market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Traumatic Brain Injury Unmet Needs, KOL’s views, Analyst’s views, Traumatic Brain Injury Market Access and Reimbursement

To know more about Traumatic Brain Injury companies working in the treatment market, visit @ Traumatic Brain Injury Clinical Trials and Therapeutic Assessment

Table of Contents

1. Traumatic Brain Injury Market Report Introduction

2. Executive Summary for Traumatic Brain Injury

3. SWOT analysis of Traumatic Brain Injury

4. Traumatic Brain Injury Patient Share (%) Overview at a Glance

5. Traumatic Brain Injury Market Overview at a Glance

6. Traumatic Brain Injury Disease Background and Overview

7. Traumatic Brain Injury Epidemiology and Patient Population

8. Country-Specific Patient Population of Traumatic Brain Injury

9. Traumatic Brain Injury Current Treatment and Medical Practices

10. Traumatic Brain Injury Unmet Needs

11. Traumatic Brain Injury Emerging Therapies

12. Traumatic Brain Injury Market Outlook

13. Country-Wise Traumatic Brain Injury Market Analysis (2020–2034)

14. Traumatic Brain Injury Market Access and Reimbursement of Therapies

15. Traumatic Brain Injury Market Drivers

16. Traumatic Brain Injury Market Barriers

17. Traumatic Brain Injury Appendix

18. Traumatic Brain Injury Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Traumatic Brain Injury Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight

“Spinal Cord Injury Treatment Market”

Spinal Cord Injury companies are NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others.

DelveInsight’s Spinal Cord Injury Market Insights report includes a comprehensive understanding of current treatment practices, spinal cord injury emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Spinal Cord Injury Market Report

• As per DelveInsight analysis, the spinal cord injury market is expected to grow positively at a significant CAGR during the study period (2019–2032).
• March 2024: Mitsubishi Tanabe Pharma America Inc. announced a study of Phase 2 clinical trials for MT-3921. The purpose of this study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic cervical spinal cord injury. Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be randomized in a 2:1 ratio to receive MT-3921 or placebo in a double blind manner.
• March 2024: Moleac Pte Ltd announced a study of Phase 4 clinical trials for NeuroAiD. SATURN investigates the promising role of NeuroAiD in patients with spinal cord injury and will provide important information on the feasibility of conducting larger controlled trials.
• March 2024: NervGen Pharma announced a study of Phase 1 & 2 clinical trials for NVG-291. To evaluate the effect of NVG-291 on descending connectivity in subjects with subacute and chronic SCI (20 subjects per Cohort and results will be analyzed separately) using objective electrophysiological measures, in addition to clinical assessments. To evaluate safety and tolerability of NVG-291 in a SCI population, as measured by clinical assessments (Physical Examination, Vital Signs, ECG, etc.) as well as clinical laboratory measures.
• As per the DelveInsight assessment, the total diagnosed cases of SCI in the 7MM was estimated to be ~725K cases in 2022, which is expected to increase in the forecast period (2022-2032).
• Leading spinal cord injury companies such as NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others are developing novel spinal cord injury drugs that can be available in the spinal cord injury market in the coming years.
• Some key therapies for spinal cord injury treatment include NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, MT-3921, Elezanumab, and others.

Discover which therapies are expected to grab the major spinal cord injury market share @ Spinal Cord Injury Market Report

Spinal Cord Injury Overview

Spinal cord injury is a debilitating condition resulting from trauma or disease that damages the spinal cord, impairing motor, sensory, and autonomic functions below the level of injury. Common causes include motor vehicle accidents, falls, sports injuries, and medical conditions like tumors or infections. Spinal cord injury can be classified as complete, with total loss of function, or incomplete, where some sensation or movement remains.

The severity of Spinal cord injury depends on the location and extent of damage. Injuries to the cervical spine can result in quadriplegia, affecting all four limbs, whereas injuries to the thoracic, lumbar, or sacral regions typically cause paraplegia, involving the lower body.

Spinal cord injury Symptoms vary widely and may include paralysis, loss of sensation, pain, spasticity, and autonomic dysfunction affecting bladder, bowel, and cardiovascular regulation. Acute Spinal cord injury is a medical emergency requiring immediate stabilization to prevent further damage.

Spinal cord injury Treatment focuses on minimizing damage and promoting recovery. Initial care includes immobilization, corticosteroids to reduce inflammation, and surgical intervention when needed. Long-term management involves physical rehabilitation, occupational therapy, and assistive technologies to improve independence. Advances in regenerative medicine, including stem cell therapy, neuroprosthetics, and electrical stimulation, offer hope for improving outcomes and quality of life for individuals with Spinal cord injury.

Request for sample report @ https://www.delveinsight.com/sample-request/spinal-cord-injury-market

Spinal Cord Injury Epidemiology Segmentation

The spinal cord injury epidemiology section provides insights into the historical and current spinal cord injury patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The spinal cord injury market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Spinal Cord Injury Cases
• Spinal Cord Injury Diagnosed Cases
• Spinal Cord Injury Gender-specific Cases
• Spinal Cord Injury Cause-specific Cases
• Total cases of SCI at Neurological Level

Spinal Cord Injury Treatment Market

In the initial care of a patient with a spinal cord injury, the foremost priority is to establish and secure the airway, ensure proper breathing, and maintain circulation. This is followed by the crucial step of immobilizing the spine in the field to prevent any further harm to the vulnerable spinal cord during transportation. It is of paramount importance to recognize and triage SCI patients appropriately in the early stages to guarantee the prompt delivery of specialized treatments at dedicated centers.

While maintaining spinal immobilization, airway, and breathing management can vary from administering supplemental oxygen to performing intubation and providing mechanical ventilation. At any stage during the initial injury, the presence of systemic hypotension (defined as a systolic blood pressure [SBP] of less than 90 mmHg) is correlated with poorer neurological outcomes. Profound loss of vascular tone and the possibility of bradycardia can lead patients to quickly progress into neurogenic shock. The primary treatment approach revolves around administering large volumes of intravenous (IV) fluids, primarily crystalloids. However, healthcare providers may also opt to use additional alpha-adrenergic vasopressor medications such as norepinephrine and phenylephrine to temporarily stabilize patients.

Currently, there is no consensus on the optimal methods for diagnosing and treating different aspects of spinal cord injuries. This lack of agreement is partly a result of the diversity in injury patterns (cervical versus thoracic, complete versus incomplete) and contradictory interpretations of available literature.

To know more about spinal cord injury treatment, visit @ Spinal Cord Injury Treatment Drugs

Key Spinal Cord Injury Therapies and Companies

• NVG-291: NervGen Pharma
• Romosozumab: VA Office of Research and Development/Kessler Institute for Rehabilitation
• Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc.
• MT-3921: Mitsubishi Tanabe Pharma America Inc.
• Elezanumab: AbbVie

Learn more about the FDA-approved drugs for spinal cord injury @ Drugs for Spinal Cord Injury Treatment

Spinal Cord Injury Market Dynamics

The dynamics of the spinal cord injury market are expected to change in the coming years. Both academic institutions and industries are actively pursuing advanced approaches to the development of innovative therapies. Recent advancements in comprehending the pathophysiology of spinal cord injuries have triggered a notable increase in clinical trials. Continuous dedication to basic and clinical research is forging a new path toward regenerative medicine in SCI. Nevertheless, the lack of an efficient therapy to target SCI-related symptoms and complications remains a pressing issue.

Furthermore, many potential therapies are being investigated for the treatment of spinal cord injury, and it is safe to predict that the treatment space will significantly impact the spinal cord injury market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the spinal cord injury market in the 7MM.

However, several factors are impeding the growth of the spinal cord injury market. Many researchers maintain a sense of skepticism and caution regarding the practicality of stem cell therapies. The pricing and accessibility issues surrounding these treatments continue to be a significant point of contention. A substantial portion of clinical trials has fallen short of achieving their intended outcomes, often due to a lack of understanding of the disease’s underlying causes and suboptimal trial designs. The early approval of stem cell-based treatments can lead to patients opting for experimental therapies, which may carry risks and prove ineffective, placing a heavy financial burden on both patients and insurance providers.

Moreover, spinal cord injury treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the spinal cord injury market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the spinal cord injury market growth.

Scope of the Spinal Cord Injury Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Spinal Cord Injury Companies: NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others
• Key Spinal Cord Injury Therapies: NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, MT-3921, Elezanumab, and others
• Therapeutic Assessment: Spinal Cord Injury current marketed and emerging therapies
• Spinal Cord Injury Market Dynamics: Conjoint Analysis of Emerging Spinal Cord Injury Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Spinal Cord Injury Market Access and Reimbursement

Discover more about spinal cord injury drugs in development @ Spinal Cord Injury Clinical Trials

Table of Contents

1. Spinal Cord Injury Market Key Insights

2. Spinal Cord Injury Market Report Introduction

3. Spinal Cord Injury Market Overview at a Glance

4. Spinal Cord Injury Market Executive Summary

5. Disease Background and Overview

6. Spinal Cord Injury Treatment and Management

7. Spinal Cord Injury Epidemiology and Patient Population

8. Patient Journey

9. Spinal Cord Injury Marketed Drugs

10. Spinal Cord Injury Emerging Drugs

11. Seven Major Spinal Cord Injury Market Analysis

12. Spinal Cord Injury Market Outlook

13. Potential of Current and Emerging Therapies

14. KOL Views

15. Unmet Needs

16. SWOT Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spinal Cord Injury Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight

“Tenosynovial Giant Cell Tumors Treatment Market”

(Albany, USA) DelveInsight’s “Tenosynovial Giant Cell Tumors Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Tenosynovial Giant Cell Tumors, historical and forecasted epidemiology as well as the Tenosynovial Giant Cell Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Tenosynovial Giant Cell Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Tenosynovial Giant Cell Tumors Market Forecast

Some of the key facts of the Tenosynovial Giant Cell Tumors Market Report:

• The Tenosynovial Giant Cell Tumors market size was valued approximately USD 300 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In April 2024, SynOx Therapeutics secured USD 75 million in Series B funding. The raised capital will be allocated towards obtaining registrational Phase 3 clinical data and chemistry, manufacturing, and controls (CMC) data for emactuzumab, a monoclonal antibody (mAb) inhibiting CSF-1(R), intended for treating tenosynovial giant cell tumor (TGCT).
• In the seven major markets (7MM), localized tenosynovial giant cell tumor (TGCT) comprised approximately 80% of all TGCT cases in 2023.
• In the seven major markets (7MM), localized tenosynovial giant cell tumor (TGCT) was predominantly located in the digits, representing approximately 75% of all cases in 2023.
• Giant cell tumors can manifest in various joints such as the knee, ankle, and hip, depending on whether they are localized or diffuse. DelveInsight’s estimates suggest that for diffuse TGCT, the highest tumor localization was observed in the knee, with approximately 30,000 cases in the United States in 2023.
• Despite the introduction of novel CSF1R inhibitors, the market size of off-label systemic therapies (such as imatinib, sunitinib, and others) is anticipated to exhibit stagnant growth in the forecast period. This is attributed to the rising prevalence of cases in the seven major markets (7MM).
• Key Tenosynovial Giant Cell Tumors Companies: Daiichi Sankyo Co., Ltd., Deciphera Pharmaceuticals, Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics Limited, Abbisko Therapeutics, Five Prime Therapeutics, Novartis, and others
• Key Tenosynovial Giant Cell Tumors Therapies: Pexidartinib, vimseltinib, AMB-05X, Emactuzumab, Pimicotinib(ABSK021), FPA008, MCS110, and others
• The Tenosynovial Giant Cell Tumors market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tenosynovial Giant Cell Tumors pipeline products will significantly revolutionize the Tenosynovial Giant Cell Tumors market dynamics.

Tenosynovial Giant Cell Tumors Overview

Tenosynovial giant cell tumors (TGCTs) are rare, benign, and typically slow-growing tumors that affect the synovium, tendon sheaths, or bursae within joints. These tumors are classified into two main types: localized TGCT (L-TGCT) and diffuse TGCT (D-TGCT), formerly known as pigmented villonodular synovitis (PVNS).

L-TGCT is more common, presenting as a well-circumscribed nodule, often in the hands or fingers. In contrast, D-TGCT involves large joints like the knee or hip and is more aggressive, causing widespread joint damage. Both types are associated with joint swelling, pain, stiffness, and restricted mobility.

The etiology of TGCT is not fully understood but is thought to involve chromosomal abnormalities and overexpression of colony-stimulating factor 1 (CSF1), which attracts macrophages and leads to tumor growth.

Diagnosis involves imaging such as MRI, which highlights the extent of the lesion, and biopsy for histological confirmation.

Treatment typically includes surgical removal, with arthroscopic techniques preferred for smaller tumors and open surgery for extensive cases. For recurrent or unresectable D-TGCT, targeted therapies like CSF1R inhibitors (e.g., pexidartinib) may be effective. Early detection and treatment are crucial to minimize joint damage and improve outcomes.

Get a Free sample for the Tenosynovial Giant Cell Tumors Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market

Tenosynovial Giant Cell Tumors Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Tenosynovial Giant Cell Tumors Epidemiology Segmentation:

The Tenosynovial Giant Cell Tumors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Tenosynovial Giant Cell Tumors
• Prevalent Cases of Tenosynovial Giant Cell Tumors by severity
• Gender-specific Prevalence of Tenosynovial Giant Cell Tumors
• Diagnosed Cases of Episodic and Chronic Tenosynovial Giant Cell Tumors

Download the report to understand which factors are driving Tenosynovial Giant Cell Tumors epidemiology trends @ Tenosynovial Giant Cell Tumors Epidemiology Forecast

Tenosynovial Giant Cell Tumors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tenosynovial Giant Cell Tumors market or expected to get launched during the study period. The analysis covers Tenosynovial Giant Cell Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Tenosynovial Giant Cell Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Tenosynovial Giant Cell Tumors Therapies and Key Companies

• Pexidartinib: Daiichi Sankyo Co., Ltd.
• vimseltinib: Deciphera Pharmaceuticals
• Pimicotinib(ABSK021): Abbisko Therapeutics
• AMB-05X: AmMax Bio, Inc.
• Emactuzumab: SynOx Therapeutics Limited
• Pimicotinib(ABSK021): Abbisko Therapeutics
• FPA008: Five Prime Therapeutics
• MCS110: Novartis

Discover more about therapies set to grab major Tenosynovial Giant Cell Tumors market share @ Tenosynovial Giant Cell Tumors Treatment Landscape

Scope of the Tenosynovial Giant Cell Tumors Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Tenosynovial Giant Cell Tumors Companies: Daiichi Sankyo Co., Ltd., Deciphera Pharmaceuticals, Abbisko Therapeutics, AmMax Bio, Inc., SynOx Therapeutics Limited, Abbisko Therapeutics, Five Prime Therapeutics, Novartis, and others
• Key Tenosynovial Giant Cell Tumors Therapies: Pexidartinib, vimseltinib, AMB-05X, Emactuzumab, Pimicotinib(ABSK021), FPA008, MCS110, and others
• Tenosynovial Giant Cell Tumors Therapeutic Assessment: Tenosynovial Giant Cell Tumors current marketed and Tenosynovial Giant Cell Tumors emerging therapies
• Tenosynovial Giant Cell Tumors Market Dynamics: Tenosynovial Giant Cell Tumors market drivers and Tenosynovial Giant Cell Tumors market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Tenosynovial Giant Cell Tumors Unmet Needs, KOL’s views, Analyst’s views, Tenosynovial Giant Cell Tumors Market Access and Reimbursement

To know more about Tenosynovial Giant Cell Tumors companies working in the treatment market, visit @ Tenosynovial Giant Cell Tumors Clinical Trials and Therapeutic Assessment

Table of Contents

1. Tenosynovial Giant Cell Tumors Market Report Introduction

2. Executive Summary for Tenosynovial Giant Cell Tumors

3. SWOT analysis of Tenosynovial Giant Cell Tumors

4. Tenosynovial Giant Cell Tumors Patient Share (%) Overview at a Glance

5. Tenosynovial Giant Cell Tumors Market Overview at a Glance

6. Tenosynovial Giant Cell Tumors Disease Background and Overview

7. Tenosynovial Giant Cell Tumors Epidemiology and Patient Population

8. Country-Specific Patient Population of Tenosynovial Giant Cell Tumors

9. Tenosynovial Giant Cell Tumors Current Treatment and Medical Practices

10. Tenosynovial Giant Cell Tumors Unmet Needs

11. Tenosynovial Giant Cell Tumors Emerging Therapies

12. Tenosynovial Giant Cell Tumors Market Outlook

13. Country-Wise Tenosynovial Giant Cell Tumors Market Analysis (2020–2034)

14. Tenosynovial Giant Cell Tumors Market Access and Reimbursement of Therapies

15. Tenosynovial Giant Cell Tumors Market Drivers

16. Tenosynovial Giant Cell Tumors Market Barriers

17. Tenosynovial Giant Cell Tumors Appendix

18. Tenosynovial Giant Cell Tumors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Tenosynovial Giant Cell Tumors Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight

“Mydriasis Treatment Market”

(Albany, USA) DelveInsight’s “Mydriasis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Mydriasis, historical and forecasted epidemiology as well as the Mydriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Mydriasis, offering comprehensive insights into the Mydriasis revenue trends, prevalence, and treatment landscape. The report delves into key Mydriasis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Mydriasis therapies. Additionally, we cover the landscape of Mydriasis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Mydriasis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Mydriasis space.

To Know in detail about the Mydriasis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Mydriasis Market Forecast

Some of the key facts of the Mydriasis Market Report:

• The Mydriasis market size was valued ~USD 604 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2023, the total market size for Mydriasis in the US was around USD 378.6 million, representing approximately 63% of the overall market revenue across the 7MM.
• In 2023, the total market size for Mydriasis in EU4 and the UK was estimated to be around USD 150.4 million. Germany held the largest share with approximately USD 42.7 million, followed by France with USD 36.5 million, and the UK with USD 28.3 million.
• In 2023, the market size for Mydriasis in Japan was estimated to be around USD 75.4 million.
• In 2023, the largest market share among current therapies was held by topical treatments (eye drops/irrigation) for surgeries, generating around USD 286.2 million in the 7MM. This was followed by topical treatments (eye drops/irrigation) for eye exams, with a revenue of approximately USD 183.5 million, and OMIDRIA, which earned approximately USD 112.1 million.
• Key Mydriasis Companies: Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd., and others
• Key Mydriasis Therapies: RYZUMVI (Phentolamine Ophthalmic Solution 0.75%), MYDCOMBI, OMIDRIA, MydCombi, CTO0303-A, and others
• The Mydriasis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mydriasis pipeline products will significantly revolutionize the Mydriasis market dynamics.
• DelveInsight’s epidemiology model estimates that there were around 352.1 million eye examinations and ophthalmic surgeries in the 7MM in 2023. This number is projected to grow over the forecast period (2024-2034), driven by the increasing prevalence of age-related eye conditions like cataracts, glaucoma, and macular degeneration, which are expected to result in a higher demand for eye exams and surgeries.
• In 2023, out of the total eye examinations and ophthalmic surgeries in the 7MM, around 338.0 million were eye exams and check-ups. Additionally, there were approximately 8.6 million cataract surgeries, 538 thousand glaucoma surgeries, 1.6 million refractive surgeries, 505 thousand vitreoretinal surgeries, and 2.9 million cases involving other types of surgeries.
• In 2023, the US made up 53% of the total eye examinations and ophthalmic surgeries, while EU4 and the UK accounted for 32%, and Japan contributed 15% of the cases.
• In 2023, there were around 65.1 million instances of pupil dilation for eye examinations and approximately 5.1 million cases for eye surgeries in the EU4 countries and the UK.
• In 2023, Germany led the EU4 and the UK with the highest number of pupil dilation cases, recording 16.7 million for eye examinations and 1.5 million for surgeries. France followed with about 13.5 million cases for eye examinations and 1.3 million for surgeries. Spain had the lowest figures, with 9.3 million pupil dilation cases for eye exams and 634 thousand for surgeries.
• In 2023, Japan recorded approximately 29.7 million cases of pupil dilation for eye examinations and around 2.5 million cases for eye surgeries. These figures are anticipated to shift throughout the forecast period.

Mydriasis Overview

Mydriasis refers to the dilation of the pupils, which can occur naturally or be induced for medical purposes. It is commonly achieved through the use of mydriatic agents (eye drops or irrigation solutions) during eye examinations or ophthalmic surgeries to enable a better view of the retina, optic nerve, and other internal structures of the eye. Mydriasis is important for diagnosing eye conditions like cataracts, glaucoma, and retinal diseases, as well as for performing surgeries such as cataract removal and refractive surgeries. While pupil dilation is a temporary condition, it can also be a symptom of certain medical issues or neurological disorders.

Get a Free sample for the Mydriasis Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/mydriasis-market

Mydriasis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Mydriasis Epidemiology Segmentation:

The Mydriasis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

• Total Prevalence of Mydriasis
• Prevalent Cases of Mydriasis by severity
• Gender-specific Prevalence of Mydriasis
• Diagnosed Cases of Episodic and Chronic Mydriasis

Download the report to understand which factors are driving Mydriasis epidemiology trends @ Mydriasis Epidemiology Forecast

Mydriasis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mydriasis market or expected to get launched during the study period. The analysis covers Mydriasis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Mydriasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Mydriasis Therapies and Key Companies

• RYZUMVI (Phentolamine Ophthalmic Solution 0.75%): Viatris/Ocuphire Pharma
• MYDCOMBI: Eyenovia
• OMIDRIA: Rayner Surgical/Omeros
• MydCombi: Eyenovia Inc.
• CTO0303-A: Taejoon Pharmaceutical Co., Ltd.

Discover more about therapies set to grab major Mydriasis market share @ Mydriasis Treatment Landscape

Mydriasis Market Drivers

• Increasing Prevalence of Eye Conditions
• Technological Advancements
• Aging Population
• Increased Awareness of Eye Health
• Surge in Ophthalmic Surgeries

Mydriasis Market Barriers

• High Cost of Treatment
• Side Effects of Mydriatic Agents
• Limited Availability in Low-Resource Settings
• Competition from Alternative Therapies
• Stringent Regulatory Approval

Scope of the Mydriasis Market Report

• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Mydriasis Companies: Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd., and others
• Key Mydriasis Therapies: RYZUMVI (Phentolamine Ophthalmic Solution 0.75%), MYDCOMBI, OMIDRIA, MydCombi, CTO0303-A, and others
• Mydriasis Therapeutic Assessment: Mydriasis current marketed and Mydriasis emerging therapies
• Mydriasis Market Dynamics: Mydriasis market drivers and Mydriasis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Mydriasis Unmet Needs, KOL’s views, Analyst’s views, Mydriasis Market Access and Reimbursement

To know more about Mydriasis companies working in the treatment market, visit @ Mydriasis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Mydriasis Market Report Introduction

2. Executive Summary for Mydriasis

3. SWOT analysis of Mydriasis

4. Mydriasis Patient Share (%) Overview at a Glance

5. Mydriasis Market Overview at a Glance

6. Mydriasis Disease Background and Overview

7. Mydriasis Epidemiology and Patient Population

8. Country-Specific Patient Population of Mydriasis

9. Mydriasis Current Treatment and Medical Practices

10. Mydriasis Unmet Needs

11. Mydriasis Emerging Therapies

12. Mydriasis Market Outlook

13. Country-Wise Mydriasis Market Analysis (2020-2034)

14. Mydriasis Market Access and Reimbursement of Therapies

15. Mydriasis Market Drivers

16. Mydriasis Market Barriers

17. Mydriasis Appendix

18. Mydriasis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mydriasis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight